1,627 matches
-
Fountzilas G et al. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation în small cell lung cancer: a randomized phase III study. Semin Oncol 1994; 21 (suppl 6): 23-30. 14. O'Brien ME, Ciuleanu TE, Tsekov H et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan în patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24: 5441-5447. Mezoteliomul pleural malign Recomandările ESMO pentru diagnosticare, tratament și monitorizare R. Stahel*1), W. Wedre*2) amp
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
183 patients. J Thorac Cardiovasc Surg 1999; 17: 54-63. 5. Waller DA. The role of surgery în diagnosis and treatment of malignant pleural mesothelioma. Curr Opin Oncol 2003; 15: 139-143. 6. Weder W, Stahel RA, Bernhard J et al. Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy în malignant pleural mesothelioma. Ann Oncol 2007; 18: 11961202. 7. Rice DC, Smythe WR, Liao Z et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
DC, Smythe WR, Liao Z et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2007; 69: 350-357. 8. O'Rourke N, Garcia JC, Paul J et al. A randomized controlled trial of intervention site radiotherapy în malignant pleural mesothelioma. Radiother Oncol 2007; 84: 18-22. 9. Ellis P, Davies AM, Evans WK et al. The use of chemotherapy în patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
with or without raltitrexed în patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and Național Cancer Institute, Canada. Intergroup Study. J Clin Oncol 2006; 24: 1435-1442. 14. Jassem J, Ramlau R, Santoro A et al. A randomised phase III trial comparing pemetrexed plus best supportive care vs best supportive care în previously treated patients with advanced malignant mesothelioma. Ann Oncol 2006; 17 (Suppl 9): Abstr 7150. 15. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response în malignant
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality în a randomized European study. N Engl J Med 2009; 13: 360. 2. Andriole GL, Grupp RL III, Buys SS et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 13: 360. 3. Thompson IM et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-534. 4. Gleave ME, Coupland D, Drachenberg D et al. Ability
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
2. Andriole GL, Grupp RL III, Buys SS et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 13: 360. 3. Thompson IM et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-534. 4. Gleave ME, Coupland D, Drachenberg D et al. Ability of serum prostate-specific antigen levels to predict normal bone scans în patients with newly diagnosed prostate cancer. Urology 1996; 47: 708-712. 5. O
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
using conformal radiotherapy în prostate cancer: PSA control and side effects. Br J Cancer 2005; 92: 488-498. 12. Dearnaley DP et al. Escalated dose versus standard dose conformal radiotherapy în prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475487. 13. Bolla M et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-578. 14. Lawton CA, Winter K, Murray K et al. Updated results of the phase
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
DP et al. Escalated dose versus standard dose conformal radiotherapy în prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475487. 13. Bolla M et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-578. 14. Lawton CA, Winter K, Murray K et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potențial benefit of androgen suppression following standard radiation therapy
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
al. Escalated dose versus standard dose conformal radiotherapy în prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475487. 13. Bolla M et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-578. 14. Lawton CA, Winter K, Murray K et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potențial benefit of androgen suppression following standard radiation therapy for unfavourable
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Bolla M et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-578. 14. Lawton CA, Winter K, Murray K et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potențial benefit of androgen suppression following standard radiation therapy for unfavourable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937-946. 15. Pilepich MV, Winter K, John MJ et al. Phase III Radiation
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
benefit of androgen suppression following standard radiation therapy for unfavourable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937-946. 15. Pilepich MV, Winter K, John MJ et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjunct to definitive radiotherapy în locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252. 16. D'Amico et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252. 16. D'Amico et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-827. 17. Denham JW et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841-850. 18. Widmark A et
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-827. 17. Denham JW et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841-850. 18. Widmark A et al. Does prophylactic breast irradiation prevent antiandrogeninduced gynecomastia? Evaluation of 253 patients în the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 2003; 61: 145-151. 19. Tannock IF, de Witt R, Berry WR
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841-850. 18. Widmark A et al. Does prophylactic breast irradiation prevent antiandrogeninduced gynecomastia? Evaluation of 253 patients în the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 2003; 61: 145-151. 19. Tannock IF, de Witt R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512. 20. Petrylak DP, Tangen C, Hussain
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
1502-1512. 20. Petrylak DP, Tangen C, Hussain M et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520. 21. Porter AT et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation în the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805-813. 22. Quilty P et al. A comparison of the
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
vinblastine, doxorubicin în advanced or metastatic bladder cancer: results of a large randomized, multinational, phase III study. J Clin Oncol 2000; 17:3068-3077. 19. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin în patients with bladder cancer. J Clin Oncol 2005; 23:4602-4608. 20. Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
II study of sunitinib as first line treatment în patients with advanced urothelial cancer ineligibile for cisplatin-based chemotherapy. Proc 2008; ASCO Genitourinary Cancers Symposium (Abstr 291). 23. Bellmunt J, von der Maase H, Theodore C, et al. Randomized phase III trial of vinflunine (VFL) plus best supportive care (BSC) versus BSC alone as 2nd line therapy after a platinum-containing regimen, în advanced transitional cell carcinoma of the urothelium (TCCU). În: J Clin Oncol. 2008; ASCO Annual Meeting Proceedings part I, vol
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Sunitinib versus interferon alfa în metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124. 5. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111. 6. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281. 7. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
dose ��n această situație este experimentală și trebuie efectuată în cadrul studiilor clinice. Chirurgia trebuie să fie o componentă a strategiei, în special la pacienții cu boală localizată sau recidivă tardivă cu răspuns nesatisfăcător la chimioterapie. Pacienții ar trebui incluși în trialuri clinice și direcționați către centre specializate, oricând este posibil. Evaluarea răspunsului în boala metastatică Efectul tratamentului trebuie monitorizat prin măsurători (radiografie torace, CT și markeri) la o lună după terminarea tratamentului [IV, B]. În cazul existenței unei mase de țesut
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
ifosfamide în treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol (1998) 16:1287-1293. 13. Rustin GJ, Mead GM, Stenning SP, et al. Randomized trial of two or five computed tomography scans în the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197-The Național Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Oncol (1998) 16:1287-1293. 13. Rustin GJ, Mead GM, Stenning SP, et al. Randomized trial of two or five computed tomography scans în the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197-The Național Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol (2007) 25:1310-1315. 14. de Wit R, Fizazi K. Controversies în the management of clinical stage I testis cancer. J Clin Oncol (2006) 24:5482-5492. 15
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Oncol (2006) 24:5482-5492. 15. Huddart R, Kataja V. Mixed or non-seminomatous germ-cell tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 19(Suppl 2):ii52-ii54. 16. Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy în the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol (2005) 16:1152-1159. Tumorile germinale testiculare non-seminomatoase: Recomandările ESMO pentru diagnostic, tratament și urmărire H.-J. Schmoll*1), K. Jordan
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
ifosfamide în treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol (1998) 16:1287-1293. 13. Rustin GJ, Mead GM, Stenning SP, et al. Randomized trial of two or five computed tomography scans în the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197-The Național Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Oncol (1998) 16:1287-1293. 13. Rustin GJ, Mead GM, Stenning SP, et al. Randomized trial of two or five computed tomography scans în the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197-The Național Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 2007; 25:1310-1315. 14. de Wit R, Fizazi K. Controversies în the management of clinical stage I testis cancer. J Clin Oncol 2006; 24:5482-5492. 15
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Oncol 2006; 24:5482-5492. 15. Huddart R, Kataja V. Mixed or non-seminomatous germ-cell tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19(Suppl 2) :ii52-ii54. 16. Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy în the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005; 16:1152-1159. MIELOMUL MULTIPLU RECOMANDARILE CLINICE ESMO PENTRU DIAGNOSTIC, TRATAMENT ȘI MONITORIZARE J.-L. Harousseau*1) amp; M. Dreyling
EUR-Lex () [Corola-website/Law/227406_a_228735]